Tubeimoside-2 Triggers Methuosis in Hepatocarcinoma Cells through the MKK4–p38α Axis

Liver cancer, consisting mainly of hepatocellular carcinoma, is the third leading cause of cancer-related mortality worldwide. Despite advances in targeted therapies, these approaches remain insufficient in meeting the pressing clinical demands. Here, we present a novel alternative that calls for a non-apoptotic program to solve the current dilemma. Specifically, we identified that tubeimoside 2 (TBM-2) could induce methuosis in hepatocellular carcinoma cells, a recently recognized mode of cell death characterized by pronounced vacuolization, necrosis-like membrane disruption, and no response to caspase inhibitors. Further proteomic analysis revealed that TBM-2-driven methuosis is facilitated by the hyperactivation of the MKK4–p38α axis and the boosted lipid metabolism, especially cholesterol biosynthesis. Pharmacological interventions targeting either the MKK4–p38α axis or cholesterol biosynthesis effectively suppress TBM-2-induced methuosis, highlighting the pivotal role of these mechanisms in TBM-2-mediated cell death. Moreover, TBM-2 treatment effectively suppressed tumor growth by inducing methuosis in a xenograft mouse model of hepatocellular carcinoma. Taken together, our findings provide compelling evidence of TBM-2’s remarkable tumor-killing effects by inducing methuosis, both in vitro and in vivo. TBM-2 represents a promising avenue for the development of innovative and effective therapies for hepatocellular carcinoma, one that may ultimately offer significant clinical benefits for patients with this devastating disease.

[1]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[2]  Y. Fuchs,et al.  Modes of Regulated Cell Death in Cancer. , 2021, Cancer discovery.

[3]  Yueling Li,et al.  Macropinocytosis as a cell entry route for peptide-functionalized and bystander nanoparticles. , 2020, Journal of controlled release : official journal of the Controlled Release Society.

[4]  J. Stow,et al.  Macropinocytosis: Insights from immunology and cancer. , 2020, Current opinion in cell biology.

[5]  E. D. De Toni,et al.  The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects , 2020, Signal Transduction and Targeted Therapy.

[6]  B.L.C. Noir,et al.  defining , 2020, Catalysis from A to Z.

[7]  A. Edinger,et al.  Macropinocytosis confers resistance to therapies targeting cancer anabolism , 2020, Nature Communications.

[8]  P. Devreotes,et al.  Statin-induced GGPP depletion blocks macropinocytosis and starves cells with oncogenic defects , 2020, Proceedings of the National Academy of Sciences.

[9]  D. Bar-Sagi,et al.  Plasma membrane v-ATPase controls oncogenic Ras-induced macropinocytosis , 2019, Nature.

[10]  M. Athar,et al.  Combined mTORC1/mTORC2 inhibition blocks growth and induces catastrophic macropinocytosis in cancer cells , 2019, Proceedings of the National Academy of Sciences.

[11]  Hongyang Wang,et al.  Targeted therapy for hepatocellular carcinoma: Challenges and opportunities. , 2019, Cancer letters.

[12]  Gregory J. Gores,et al.  A global view of hepatocellular carcinoma: trends, risk, prevention and management , 2019, Nature Reviews Gastroenterology & Hepatology.

[13]  V. Rotter,et al.  Liver and Steroid Hormones—Can a Touch of p53 Make a Difference? , 2019, Front. Endocrinol..

[14]  Yijuan Zhang,et al.  Macropinocytosis in Cancer: A Complex Signaling Network. , 2019, Trends in cancer.

[15]  Ping Li,et al.  Phellodendrine chloride suppresses proliferation of KRAS mutated pancreatic cancer cells through inhibition of nutrients uptake via macropinocytosis , 2019, European journal of pharmacology.

[16]  A. F. Castro,et al.  CK2 inhibition with silmitasertib promotes methuosis-like cell death associated to catastrophic massive vacuolization of colorectal cancer cells , 2019, Cell Death & Disease.

[17]  Yongliang Zhu,et al.  The potential role of tubeimosides in cancer prevention and treatment. , 2019, European journal of medicinal chemistry.

[18]  Jie He,et al.  Liver cancer incidence and mortality in China: Temporal trends and projections to 2030 , 2018, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[19]  D. DiMaio,et al.  SV40 Polyomavirus Activates the Ras-MAPK Signaling Pathway for Vacuolization, Cell Death, and Virus Release , 2018, bioRxiv.

[20]  S. Lipton,et al.  Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018 , 2018, Cell Death & Differentiation.

[21]  S. Lipton,et al.  Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018 , 2018, Cell Death & Differentiation.

[22]  G. Chen,et al.  New insights into sorafenib resistance in hepatocellular carcinoma: Responsible mechanisms and promising strategies. , 2017, Biochimica et biophysica acta. Reviews on cancer.

[23]  M. V. Recouvreux,et al.  Macropinocytosis: A Metabolic Adaptation to Nutrient Stress in Cancer , 2017, Front. Endocrinol..

[24]  T. Soga,et al.  Cancer with low cathepsin D levels is susceptible to vacuolar (H+)‐ATPase inhibition , 2017, Cancer science.

[25]  Yaojin Peng,et al.  Tubeimoside-1 suppresses breast cancer metastasis through downregulation of CXCR4 chemokine receptor expression , 2016, BMB reports.

[26]  Debra L. Fulton,et al.  p38 Mitogen-Activated Protein Kinase Pathway Regulates Genes during Proliferation and Differentiation in Oligodendrocytes , 2015, PloS one.

[27]  Rongying Zhang,et al.  The effect of the size of fluorescent dextran on its endocytic pathway , 2015, Cell biology international.

[28]  Joshua C. Johnson,et al.  Pyridinyl imidazole inhibitors of p38 MAP kinase impair viral entry and reduce cytokine induction by Zaire ebolavirus in human dendritic cells. , 2014, Antiviral research.

[29]  W. Maltese,et al.  Methuosis: nonapoptotic cell death associated with vacuolization of macropinosome and endosome compartments. , 2014, The American journal of pathology.

[30]  P. Johnston,et al.  Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.

[31]  M. Fujii,et al.  Dissecting the roles of Rac1 activation and deactivation in macropinocytosis using microscopic photo-manipulation , 2013, Scientific Reports.

[32]  A. Zhu New agents on the horizon in hepatocellular carcinoma , 2013, Therapeutic advances in medical oncology.

[33]  P. He,et al.  Tubeimoside-1 inhibits proliferation and induces apoptosis by increasing the Bax to Bcl-2 ratio and decreasing COX-2 expression in lung cancer A549 cells. , 2010, Molecular medicine reports.

[34]  Ari Helenius,et al.  Virus entry by macropinocytosis , 2009, Nature Cell Biology.

[35]  R. Teasdale,et al.  Defining Macropinocytosis , 2009, Traffic.

[36]  V. B. Konkimalla,et al.  From traditional Chinese medicine to rational cancer therapy. , 2007, Trends in molecular medicine.

[37]  Yong Jiang,et al.  Characterization of the Structure and Function of the Fourth Member of p38 Group Mitogen-activated Protein Kinases, p38δ* , 1997, The Journal of Biological Chemistry.

[38]  P. Hao,et al.  Eltrombopag binds SDC4 directly and enhances MAPK signaling and macropinocytosis in cancer cells. , 2022, American journal of cancer research.

[39]  A. Ivanov Exocytosis and Endocytosis , 2008, Methods in Molecular Biology.

[40]  A. Ivanov,et al.  Pharmacological inhibition of endocytic pathways: is it specific enough to be useful? , 2008, Methods in molecular biology.